Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multicenter Trial of ESK981 in Patients With Select Solid Tumors

NCT05988918 is registered in ClinicalTrials.gov with University of Michigan Rogel Cancer Center as lead sponsor.

NCT NCT05988918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05988918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multicenter Trial of ESK981 in Patients With Select Solid Tumors
Lead sponsor
University of Michigan Rogel Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 19, 2024
Completion date
August 31, 2027
Enrollment
17 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adenosquamous carcinoma, gastrointestinal neuroendocrine carcinoma, gastrointestinal neuroendocrine tumor, neuroendocrine prostate carcinoma, pancreatic adenocarcinoma, pancreatic neuroendocrine carcinoma, pancreatic neuroendocrine tumor